{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:56:04Z","timestamp":1792162564095,"version":"4.4.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031894","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T22:51:26Z","timestamp":1329864686000},"page":"e31894","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs"],"prefix":"10.1371","volume":"7","author":[{"given":"Aaron S.","family":"Kesselheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"ref1","year":"1983"},{"key":"ref2","article-title":"How drugs for rare diseases became lifeline for companies.","author":"G Anand","year":"2005"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.healthpol.2009.12.001","article-title":"The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?","volume":"95","author":"O Wellman-Labadie","year":"2010","journal-title":"Health Policy"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(08)60873-9","article-title":"Does orphan drug legislation really answer the needs of patients?","volume":"371","author":"ME Haffner","year":"2008","journal-title":"Lancet"},{"key":"ref5","first-page":"125","article-title":"The Orphan Drug Act: an engine of innovation? At what cost?","volume":"55","author":"DD Rohde","year":"2000","journal-title":"Food Drug Law J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions.","volume":"96","author":"RC Griggs","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00019053-199508050-00002","article-title":"The economics of orphan drug policy in the US. Can the legislation be improved?","volume":"8","author":"JW Peabody","year":"1995","journal-title":"Pharmacoeconomics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.healthpol.2009.12.001","article-title":"The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?","volume":"95","author":"O Wellman-Labadie","year":"2010","journal-title":"Health Policy"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2307\/3350258","article-title":"Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.","volume":"73","author":"PS Arno","year":"1995","journal-title":"Milbank Quarterly"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/009885880503100210","article-title":"Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses?","volume":"31","author":"D Loughnot","year":"2005","journal-title":"American Journal of Law and Medicine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1468-0009.2011.00636.x","article-title":"An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.","volume":"89","author":"AS Kesselheim","year":"2011","journal-title":"Milbank Quarterly"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians.","volume":"166","author":"DC Radley","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-154-8-201104190-00002","article-title":"Off-label use of recombinant Factor VIIa in U.S. hospitals: analysis of hospital records.","volume":"154","author":"AC Logan","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMp078100","article-title":"Erythropoietin, the FDA, and oncology.","volume":"356","author":"R Steinbrook","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"ref15","article-title":"Cutting dosage of costly drug spurs a debate.","author":"A Pollack","year":"2008"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"c6471","DOI":"10.1136\/bmj.c6471","article-title":"Orphan drug pricing may warrant a competition law investigation.","volume":"341","author":"JC Roos","year":"2010","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMc1009918","article-title":"Colchicine's other indication \u2014 effect of FDA action.","volume":"363","author":"WW Grody","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10552-007-0131-1","article-title":"Agreement of diagnosis and its date for hematologic malignancies and solid tumors between Medicare claims and cancer registry data.","volume":"18","author":"S Setoguchi","year":"2007","journal-title":"Cancer Causes Control"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.","volume":"148","author":"Y Kiyota","year":"2004","journal-title":"American Heart Journal"},{"key":"ref20"},{"key":"ref21","article-title":"FDA approved drug products. Silver Spring (MD): Food and Drug Administration.","year":"2012"},{"key":"ref22","article-title":"Researcher's Guide to the USRDS Database: 2005 Edition.","year":"2005"},{"key":"ref23","article-title":"Regression modeling strategies with applications to linear models, logistic regression and survival analysis","author":"FE Harrell","year":"2001"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"WA Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal.","volume":"118","author":"NB Finnerup","year":"2005","journal-title":"Pain"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations.","volume":"132","author":"RH Dworkin","year":"2007","journal-title":"Pain"},{"key":"ref27","article-title":"State Drug Utilization Data.","year":"2010"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1525-1497.2006.00412.x","article-title":"Primary care provider concerns about management of chronic pain in community clinic populations.","volume":"21","author":"CC Upshur","year":"2006","journal-title":"Journal of General Internal Medicine"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/fampra\/cmi019","article-title":"Chronic Fatigue Syndrome: a survey of GPs' attitudes and knowledge.","volume":"22","author":"J Bowen","year":"2005","journal-title":"Family Practice"},{"key":"ref30","article-title":"Pharmaceutical company Cephalon to pay $425 million for off-label drug marketing.","year":"2008"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJMp0908496","article-title":"Balancing innovation, access, and profits \u2014 market exclusivity for biologics.","volume":"361","author":"AB Engelberg","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"ref32","article-title":"American Association of Retired Persons report: the tier 4 phenomenon: shifting the high cost of drugs to consumers.","author":"B Walsh","year":"2009"},{"key":"ref33","first-page":"w832","article-title":"Evaluating Medicare Part D drug price reform options.","volume":"28","author":"MK Outterson","year":"2009","journal-title":"Health Affairs"},{"key":"ref34"},{"key":"ref35","first-page":"657","article-title":"Importance of distinguishing supported and unsupported off-label drug use.","volume":"170","author":"SM Walton","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1377\/hlthaff.2010.0336","article-title":"At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence.","volume":"29","author":"NK Choudhry","year":"2010","journal-title":"Health Affairs"},{"key":"ref37","first-page":"14","article-title":"An audience with\u2026Francis Collins, interviewed by Asher Mullard.","volume":"10","author":"F Collins","year":"2011","journal-title":"Nat Rev Drug Discov"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:29:39Z","timestamp":1561343379000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031894"}},"subtitle":[],"editor":[{"given":"Silvia","family":"Alessi-Severini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031894","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}